Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.

ABSTRACT:

Objective

The Non Interventional Evaluation with Golumimab (GO-NICE) study aimed to document patient and treatment characteristics as well as clinical effectiveness and safety in adult patients newly treated with the tumour necrosis factor inhibitor golimumab (GLM).

Design

Prospective non-interventional study with 24-month observation per patient.

Setting

158 office-based and clinical-based physicians in Germany.

Intervention

GLM administered in the 50 mg dose subcutaneously in monthly intervals under real-life conditions.

Results

Of the 1613 included patients, 1458 patients were eligible for final analysis: 474 patients with rheumatoid arthritis (RA, 54.9±13.4 years, 72.8% women, 64.7% biologic-naïve), 501 with psoriatic arthritis (PsA, 50.5±12.1 years,

SUBMITTER: Kruger K 

PROVIDER: S-EPMC6009562 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature